Eribulin: Rediscovering Tubulin as an Anticancer Target

被引：30

作者：

Jimeno, Antonio ^{[1
,2
,3
]}

机构：

[1] Univ Colorado, Ctr Canc, Dev Therapeut Program, Aurora, CO 80045 USA

[2] Univ Colorado, Ctr Canc, Head & Neck Canc Program, Aurora, CO 80045 USA

[3] Univ Colorado, Ctr Canc, Stem Cell Program, Aurora, CO 80045 USA

来源：

CLINICAL CANCER RESEARCH | 2009年 / 15卷 / 12期

关键词：

METASTATIC BREAST-CANCER; PHASE-III TRIAL; HALICHONDRIN-B; HOMOHALICHONDRIN-B; NATURAL-PRODUCTS; PROTEIN-TAU; BEVACIZUMAB; COMBINATION; ERLOTINIB; ANTHRACYCLINE;

D O I：

10.1158/1078-0432.CCR-09-1023

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Eribulin mesylate (E7389) is a synthetic analog of the marine macrolide halichondrin B, which acts as a novel microtubule modulator with a distinct mechanism of action. Two eribulin mesylate phase 1 studies exploring weekly and 3-weekly schedules are reported in this issue. These trials show linear pharmacokinetics, a toxicity profile consisting in neutropenia and fatigue, and early hints of antitumor activity. In this commentary we give a brief historical perspective of the halichondrins and put into context eribulin mesylate as a novel tubulin modulator.

引用

页码：3903 / 3905

页数：3

共 29 条

[1]

Agoulnik S, 2005, J CLIN ONCOL, V23, p138S

[2] TOTAL SYNTHESIS OF HALICHONDRIN-B AND NORHALICHONDRIN-B [J].

AICHER, TD ;

BUSZEK, KR ;

FANG, FG ;

FORSYTH, CJ ;

JUNG, SH ;

KISHI, Y ;

MATELICH, MC ;

SCOLA, PM ;

SPERO, DM ;

YOON, SK .

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1992, 114 (08) :3162-3164

[3] Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity [J].

Azad, Nilofer S. ;

Posadas, Edwin M. ;

Kwitkowski, Virginia E. ;

Steinberg, Seth M. ;

Jain, Lokesh ;

Annunziata, Christina M. ;

Minasian, Lori ;

Sarosy, Gisele ;

Kotz, Herbert L. ;

Premkumar, Ahalya ;

Cao, Liang ;

McNally, Deborah ;

Chow, Catherine ;

Chen, Helen X. ;

Wright, John J. ;

Kohn, Elise C. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (22) :3709-3714

[4]

BAI R, 1991, J BIOL CHEM, V266, P15882

[5] CONTRIBUTIONS TO THE STUDY OF MARINE PRODUCTS .32. THE NUCLEOSIDES OF SPONGES .1. [J].

BERGMANN, W ;

FEENEY, RJ .

JOURNAL OF ORGANIC CHEMISTRY, 1951, 16 (06) :981-987

[6] A Phase II Trial of Erlotinib in Combination with Bevacizumab in Patients with Metastatic Breast Cancer [J].

Dickler, Maura N. ;

Rugo, Hope S. ;

Eberle, CareyA. ;

Brog, Edi ;

Caravelli, James F. ;

Panageas, Katherine S. ;

Boyd, Jeff ;

Yeh, Benjamim ;

Lake, Diana E. ;

Dang, Chau T. ;

Gilewski, Teresa A. ;

Bromberg, Jacqueline F. ;

Seidman, Andrew D. ;

D'Andrea, Gabriella M. ;

Moasser, Mark M. ;

Melisko, Michele ;

Park, John W. ;

Dancey, Janet ;

Norton, Larry ;

Hudis, Clifford A. .

CLINICAL CANCER RESEARCH, 2008, 14 (23) :7878-7883

[7] Docetaxel administration schedule: From fever to tears? A review of randomised studies [J].

Engels, FK ;

Verweij, J .

EUROPEAN JOURNAL OF CANCER, 2005, 41 (08) :1117-1126

[8] Property distributions: Differences between drugs, natural products, and molecules from combinatorial chemistry [J].

Feher, M ;

Schmidt, JM .

JOURNAL OF CHEMICAL INFORMATION AND COMPUTER SCIENCES, 2003, 43 (01) :218-227

[9] Peptide leads new class of chronic pain drugs [J].

Garber, K .

NATURE BIOTECHNOLOGY, 2005, 23 (04) :399-399

[10] A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies [J].

Goel, Sanjay ;

Mita, Alain C. ;

Mita, Monica ;

Rowinsky, Eric K. ;

Chu, Quincy S. ;

Wong, Nancy ;

Desjardins, Christopher ;

Fang, Fang ;

Jansen, Mendel ;

Shuster, Dale E. ;

Mani, Sridhar ;

Takimoto, Chris H. .

CLINICAL CANCER RESEARCH, 2009, 15 (12) :4207-4212

← 1 2 3 →